



FOR IMMEDIATE RELEASE

6th July 2007

OXFORD GENE TECHNOLOGY LAUNCHES CYTOSURE™ PRODUCTS FOR THE CYTOGENETICS RESEARCH COMMUNITY

Oxford, July 6th, 2007 - Oxford Gene Technology (OGT) announces the launch of two array CGH (aCGH) products designed exclusively for the cytogenetics research community. Branded under the family name CytoSure™, Syndrome Plus and Chromosome X exon specific arrays will debut at the European Cytogenetics Association conference in Istanbul, 7th-10th July, 2007.

CytoSure Syndrome Plus is a 105,000 feature array covering the whole genome, and includes probes designed to 85 constitutional syndromes - including Cri du Chat, di Georges and Prader-Willi – and other clinically relevant regions.

CytoSure ChrX array, a 44,000 feature array, has been developed in collaboration with Dr Philippos Patsalis, Chief Executive and Medical Director at the Cyprus Institute of Neurology and Genetics in Nicosia, Cyprus. This unique design provides comprehensive coverage of all relevant clinical areas across the X chromosome at high resolution.

CytoSure arrays will be supplied with complimentary visualisation software incorporating Copy Number Variation, gene and exon annotation to ease data interpretation and build confidence.

Dr Mike Evans, CEO of Oxford Gene Technology said:” We are very excited at OGT to be launching the CytoSure family – these are the only oligonucleotide arrays designed exclusively for the cytogenetics community and will enable cytogeneticists to achieve accurate, high resolution analysis of chromosome copy number and structural changes.”

- ENDS -

For further information, please contact:

At Oxford Gene Technology:

Nicola Booton-Mander, Marketing Manager

Oxford Gene Technology

Begbroke Science Park

Sandy Lane Yarnton

Oxford OX5 1PF

T: +44 1865 856352

F: +44 1865 842116

E: products@ogt.co.uk

W: www.ogt.co.uk

Media Enquiries:

Annabel Entress, 0207 268 3002 / a.entress@northbankcommunications.com

Sarah Jeffery, 0207 268 3002 / s.jeffery@northbankcommunications.com

Notes to editors

About CytoSure™ arrays

The only oligonucleotide microarrays designed exclusively for the cytogenetics research community providing:

- enhanced detection of chromosomal abnormalities due to denser coverage of clinically relevant regions using optimal length 60mer oligonucleotides
- complimentary visualisation software based on the latest build (36 NCBI) of the human genome incorporating Copy Number Variation, gene and exon annotation to ease data interpretation and build confidence.

About aCGH

In cytogenetics, aCGH is increasingly being used for the identification of chromosomal aberrations associated with a number of related genetic disorders at a higher resolution than conventional non-array methods.

About Oxford Gene Technology

- Founded in 1995 by the pioneer of Southern Blotting, Professor Sir Edwin Southern, OGT operates out of Begbroke Business Park near Oxford, with excellent access to a growing network of life science companies
- OGT offers a comprehensive custom microarray consultancy service, from experimental design through all stages to data analysis and interpretation. It has a strong proven track record in providing custom microarray service in a range of applications, and in May 2006 announced the launch of its first microarray product, an *Escherichia coli* K12 ChIP on chip, the first ChIP microarray product to be launched as part of OGT's Prokaryotic Chip² family

The key focus areas of OGT include:

1. **Array-based application products and services** for life science research and molecular diagnostics. OGT's flexible and cost-effective, customised DNA microarray service covers a range of applications, offering specialist support and assisting customers with every aspect of their research, from initial consultation and experimental design to probe selection, array design and fabrication through to data analysis and interpretation.
2. **Development of innovative platform products** for clinical research and diagnostics
3. **Licensing.** OGT operates an open licensing policy which has successfully provided access for a number of companies to OGT's fundamental intellectual property, particularly in the area of microarrays

For further information on OGT visit <http://www.ogt.co.uk/>

- ENDS -